A Phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors

Cancer

Volumn 92, Issue 2, 2001, Pages 414-419

  Sun, Weijing ^a   Stevenson, James P ^a   Gallagher, Maryann ^a   Giantonio, Bruce ^a   Algazy, Kenneth ^a   Haller, Dan ^a   Vaughn, David ^a   Raskay, Barbara J ^a   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Combination chemotherapy; Gemcitabine; Phase I study; Topotecan; Toxicity

Indexed keywords

AMINOTRANSFERASE; DNA TOPOISOMERASE INHIBITOR; GEMCITABINE; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA METABOLISM; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FEMALE; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; THROMBOCYTOPENIA; TOPOTECAN; TREATMENT OUTCOME;

EID: 0035878628     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010715)92:2<414::AID-CNCR1337>3.0.CO;2-W     Document Type: Article

References (27)

1. Evaluation of the antitumor activity of gemcitabine (2′.2′-difluoro-2′-deoxycytidine)
2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
3. Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′-difluorodeoxycytidine and 1-b-D-arabinofluranosyl cytosine
4. Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis
5. Modulatory activity of 2′, 2′-defluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides
6. Phase II trial of gemcitabine (2′, 2′-difluorodeoxycytidine) in patients with adenocarcinoma of pancreas
7. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
8. A randomized phase II trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
9. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: Inhibition of Topoisomerase I and antitumor activity
10. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro
11. Evaluation of 9-dimethylaminomethyl-10-hydroxycampothecin against xenografts derived from adult and childhood solid tumors
12. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
13. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial
14. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
15. Evaluation of irinotecan (CPT-11) and gemcitabine (G) as single agents and in combination in small-cell lung cancer cells
16. Phase I studies with the novel nucleoside analog gemcitabine
17. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly
18. Phase II trail of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas
19. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas
20. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
21. Gemcitabine (GEM) and Topotecan (TOP): A phase I trial
22. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen
23. Phase I trial of topotecan in combination with gemcitabine in platinum-and paclitaxel-refractory epithelial ovarian cancer
24. The camptothecins
25. Topotecan-a novel topoisomerase I inhibitor: Pharmacology and clinical experience
26. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell cancer patients: A dose-finding study